Palvella Therapeutics (PVLA) Net Cash Flow (2016 - 2024)
Historic Net Cash Flow for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to $69.4 million.
- Palvella Therapeutics' Net Cash Flow rose 66173.34% to $69.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $87.6 million, marking a year-over-year increase of 255556.23%. This contributed to the annual value of $76.3 million for FY2024, which is 221248.86% up from last year.
- According to the latest figures from Q4 2024, Palvella Therapeutics' Net Cash Flow is $69.4 million, which was up 66173.34% from -$188000.0 recorded in Q3 2024.
- Palvella Therapeutics' 5-year Net Cash Flow high stood at $69.4 million for Q4 2024, and its period low was -$33.0 million during Q1 2022.
- Over the past 5 years, Palvella Therapeutics' median Net Cash Flow value was $359500.0 (recorded in 2023), while the average stood at $3.5 million.
- In the last 5 years, Palvella Therapeutics' Net Cash Flow skyrocketed by 148858.2% in 2021 and then crashed by 123574.61% in 2022.
- Palvella Therapeutics' Net Cash Flow (Quarter) stood at $1.5 million in 2020, then plummeted by 523.13% to -$6.4 million in 2021, then plummeted by 83.76% to -$11.7 million in 2022, then surged by 177.69% to $9.1 million in 2023, then soared by 661.73% to $69.4 million in 2024.
- Its Net Cash Flow stands at $69.4 million for Q4 2024, versus -$188000.0 for Q3 2024 and $10.5 million for Q2 2024.